| (Values in U.S. Thousands) | Dec, 2025 | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -77,740 | -58,710 | -68,960 | -73,320 | -57,850 |
| Net Income Growth | -32.41% | +14.86% | +5.95% | -26.74% | -67.97% |
Pmv Pharmaceuticals Inc (PMVP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
PMV Pharmaceuticals Inc.is a precision oncology company. It engages in the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutations. PMV Pharmaceuticals Inc.is headquartered in Cranbury, New Jersey.
Fiscal Year End Date: 12/31